# TYSABRI SC
Keywords: TYSABRI, subcutaneous administration, multiple sclerosis, RRMS, IV infusion, patient experience, healthcare professionals, cost savings, treatment satisfaction

> This page provides detailed information about TYSABRI SC, a subcutaneous formulation of the TYSABRI treatment for multiple sclerosis, highlighting its benefits, patient experiences, clinical studies, and cost-saving advantages compared to intravenous administration.

## Details
- [TYSABRI SC](#): Overview of the subcutaneous formulation developed to improve patient experience for those with highly active relapsing-remitting multiple sclerosis (RRMS).
- [Patient Experience](#): Insights from a patient who switched from TYSABRI IV to SC, including a video available for sharing with RRMS patients.
- [Benefits of TYSABRI SC](#): Highlights advantages such as time savings, convenience, and potential cost reductions compared to IV administration.
- [Post-Dose Observation](#): Information on reduced or removed post-dose observation times for TYSABRI SC compared to IV.
- [Safety Profile](#): Comparable safety between SC and IV formulations, with the only difference being mild injection site pain for SC.
- [EASIER Study](#): Results showing significant time and cost savings for healthcare professionals and MS centers when using TYSABRI SC.
- [TONiC-MS Study](#): Findings indicating strong patient preference for TYSABRI SC over IV, citing convenience and reduced cannulation challenges.
- [Clinical Studies](#): Summaries of DELIVER and REFINE studies comparing pharmacokinetics, efficacy, and patient outcomes between SC and IV formulations.
- [Patient Support Tools](#): Resources available for healthcare professionals to support discussions with patients about TYSABRI treatment options.